Spero Therapeutics, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 24/100
What the filing says
Spero Therapeutics entered a collaboration and license agreement with Innovent Biologics effective July 8, 2026, to develop and commercialize IBI355, a CD40L-targeting monoclonal antibody, outside Greater China (Licensee Territory). Spero paid $35 million upfront to Fortvita USA (Innovent's entity), with potential development/regulatory milestones totaling [redacted amount], sales milestones up to [redacted], and tiered royalties on net sales. Spero has exclusive rights in the Licensee Territory; Innovent retains Greater China and receives reciprocal royalty-free rights to Spero's improvements.
Why this rating
Material $35M upfront (~22% of market cap) but typical biotech licensing. Royalty rates and milestones redacted, limiting full assessment. Clinical-stage asset; no revenue impact near-term. Governance structure reasonable for partnership risk.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.